{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:10:54Z","timestamp":1792714254676,"version":"4.5.0"},"reference-count":44,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T00:00:00Z","timestamp":1285804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hexadecyloxypropyl-cidofovir (HDP-CDV) is a novel ether lipid conjugate of (S)-1-(3-hydroxy-2-phosphonoylmethoxypropyl)-cytosine (CDV) which exhibits a remarkable increase in antiviral activity against orthopoxviruses compared with CDV. In contrast to CDV, HDP-CDV is orally active and lacks the nephrotoxicity of CDV itself. Increased oral bioavailability and increased cellular uptake is facilitated by the lipid portion of the molecule which is responsible for the improved activity profile. The lipid portion of HDP-CDV is cleaved in the cell, releasing CDV which is converted to CDV diphosphate, the active metabolite. HDP-CDV is a highly effective agent against a variety of orthopoxvirus infections in animal models of disease including vaccinia, cowpox, rabbitpox and ectromelia. Its activity was recently demonstrated in a case of human disseminated vaccinia infection after it was added to a multiple drug regimen. In addition to the activity against orthopoxviruses, HDP-CDV (CMX001) is active against all double stranded DNA viruses including CMV, HSV-1, HSV-2, EBV, adenovirus, BK virus, orf, JC, and papilloma viruses, and is under clinical evaluation as a treatment for human infections with these agents.<\/jats:p>","DOI":"10.3390\/v2102213","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T11:10:35Z","timestamp":1285845035000},"page":"2213-2225","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Synthesis and Early Development of Hexadecyloxypropyl-cidofovir: An Oral Antipoxvirus Nucleoside Phosphonate"],"prefix":"10.3390","volume":"2","author":[{"given":"Karl Y.","family":"Hostetler","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Disease, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0676, USA"},{"name":"Veterans Medical Research Foundation, San Diego, CA 92161, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2010,9,30]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (1980). The Global Eradication of Smallpox: Final Report of the Global Commission for the Certification of Smallpox Eradication."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3201\/eid0403.980340","article-title":"Bioterrorism as a public health threat","volume":"4","author":"Henderson","year":"1998","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","article-title":"Smallpox as a biological weapon:medical and public health management","volume":"281","author":"Henderson","year":"1999","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1128\/JVI.75.3.1205-1210.2001","article-title":"Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox","volume":"75","author":"Robbins","year":"2001","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Clarke, T. Smallpox pill promising: New drug could thwart smallpox outbreaks. Nature News, 20 March 2002.","DOI":"10.1038\/news020318-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"Sakuma","year":"1987","journal-title":"Antivir. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1128\/AAC.32.12.1839","article-title":"Antimicrob","volume":"32","author":"Snoeck","year":"1988","journal-title":"Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jmv.1890410312","article-title":"Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice","volume":"41","author":"Neyts","year":"1993","journal-title":"J. Med. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/315190","article-title":"Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge","volume":"181","author":"Bray","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0166-3542(00)00105-4","article-title":"Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir","volume":"47","author":"Smee","year":"2000","journal-title":"Antivir. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0166-3542(01)00220-0","article-title":"Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir","volume":"54","author":"Bray","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/hep.510230503","article-title":"Liver-targeted antiviral nucleosides: Enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo","volume":"23","author":"Korba","year":"1996","journal-title":"Hepatology"},{"key":"ref_13","first-page":"653","article-title":"Lymphatic absorption of orally administered prodrugs","volume":"Volume 5","author":"Stella","year":"2007","journal-title":"Prodrugs: Challenges and Rewards"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/S0021-9258(18)99456-1","article-title":"Incorporation of dietary lecithin and lysolecithin into lymph chylomicrons in the rat","volume":"242","author":"Scow","year":"1967","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0005-2760(67)90100-2","article-title":"Absorption and metabolism of lecithin and lysolecithin by intestinal slices","volume":"137","author":"Nilsson","year":"1967","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0166-3542(84)90017-2","article-title":"Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, l-(2\u2019-deoxy-2\u2019-fluoro-P-n-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2\u00b4-deoxyuridine","volume":"4","author":"Hantz","year":"1984","journal-title":"Antivir. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0168-8278(92)90175-O","article-title":"Failure of acyclovir to enhance the antiviral effect of a lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial","volume":"14","author":"Berk","year":"1992","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0006-2952(97)82446-X","article-title":"Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro","volume":"53","author":"Hostetler","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1128\/AAC.44.7.1964-1969.2000","article-title":"Antiviral activities of oral 1-O-hexadecylpropanediol-3-phospho-acyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection","volume":"44","author":"Hostetler","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/15257770008033022","article-title":"Synthesis and antiviral evaluation of 1-O-hexadecylpropanediol-3-P-acyclovir: Efficacy against HSV-1 infection in mice","volume":"19","author":"Beadle","year":"2000","journal-title":"Nucleos. Nucleot. Nucleic Acids"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/095632020101200104","article-title":"In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecyl-propanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections","volume":"12","author":"Hostetler","year":"2001","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","article-title":"Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir","volume":"36","author":"Cundy","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Beadle, J.R. Synthesis of cidofovir and (S)-HPMPA ether lipid prodrugs. Curr. Protoc. Nucleic Acid Chem., 2007.","DOI":"10.1002\/0471142700.nc1502s29"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-1981-29317","article-title":"The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products","volume":"January","author":"Mitsunobu","year":"1981","journal-title":"Synthesis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1021\/jm050473m","article-title":"Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphono-methoxypropyl)-adenine against cytomegalovirus and orthopoxviruses","volume":"49","author":"Beadle","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_26","first-page":"104","article-title":"Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox","volume":"53","author":"Huggins","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.46.4.991-995.2002","article-title":"Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir","volume":"46","author":"Kern","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1124\/mol.63.3.678","article-title":"The increased antiviral activity of 1-O-hexadecyloxypropyl-cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism","volume":"63","author":"Aldern","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1128\/AAC.49.8.3153-3162.2005","article-title":"Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate","volume":"49","author":"Magee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/AAC.01172-07","article-title":"Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand","volume":"52","author":"Magee","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijantimicag.2003.10.010","article-title":"Effects of highly active antiviral substances on lethal vaccinia virus (IDH strain) respiratory infections in mice","volume":"23","author":"Smee","year":"2004","journal-title":"Int. J. Antimicrobial Agents."},{"key":"ref_33","unstructured":"Mucker, E.M., Baker, R.O., Beadle, J.R., Shamblin, J., Kefauver, D., Zwiers, S.H., Martinez, M., Ciesla, S., Trahan, J., Hostetler, K.Y., and Huggins, J.W. (May, January 27). Orally bioavailable alkoxyalkyl esters of cidofovir: In vitro and in vivo efficacy against orthopox viruses. In Proceedings of 16th International Conference on Antiviral Research, Savannah, GA, USA."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.virol.2003.11.015","article-title":"Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model","volume":"318","author":"Buller","year":"2004","journal-title":"Virology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/AAC.48.2.404-412.2004","article-title":"Oral treatment of cowpox and vaccinia infections in mice with ether lipid esters of cidofovir","volume":"48","author":"Quenelle","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1128\/JVI.00423-07","article-title":"Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox","volume":"81","author":"Adams","year":"2007","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2007.08.003","article-title":"Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model","volume":"77","author":"Parker","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_38","unstructured":"(2010, September 14). Progressive Vaccinia in a Military Smallpox Vaccinee\u2014United States 2009, Available online: http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm58e0519a1.htm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication, in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activity of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro","volume":"49","author":"Hartline","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Activity of ether lipid ester prodrugs of acyclic nucleoside phosphonates against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1128\/AAC.50.4.1564-1566.2006","article-title":"Ether lipid derivatives of cidofovir inhibit polyomavirus BK replication in vitro","volume":"50","author":"Randhawa","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.antiviral.2006.11.010","article-title":"In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA","volume":"75","author":"Andrei","year":"2007","journal-title":"Antivir. Res."},{"key":"ref_44","unstructured":"Lanier, R. Personal communication."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/10\/2213\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:03:30Z","timestamp":1760220210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/10\/2213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,30]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2010,10]]}},"alternative-id":["v2102213"],"URL":"https:\/\/doi.org\/10.3390\/v2102213","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,30]]}}}